• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.09% Nasdaq Up0.98%

    Alnylam Pharmaceuticals, Inc. (ALNY)

    -NasdaqGS
    129.76 Up 0.94(0.73%) 4:00PM EDT
    |After Hours : 130.30 Up 0.54 (0.42%) 4:28PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Alnylam Pharmaceuticals, Inc.
    300 Third Street
    3rd Floor
    Cambridge, MA 02142
    United States - Map
    Phone: 617-551-8200
    Fax: 617-551-8101
    Website: http://www.alnylam.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:256

    Business Summary 

    Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company’s clinical development programs include Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 that is in Phase I clinical trial for hemophilia and rare bleeding disorders; ALN-CC5, which is in Phase I/II clinical trial for the treatment of complement-mediated diseases; and ALN-PCSsc that is in Phase I clinical trial for hypercholesterolemia. Its product development programs also include ALN-AS1 for the treatment of hepatic porphyrias; ALN-AAT for the treatment of alpha-1 antitrypsin deficiency liver disease; ALN-GO1 for the treatment of primary hyperoxaluria type 1; ALN-TMP for the treatment of beta-thalassemia and iron-overload disorders; ALN-AC3 for the treatment of hypertriglyceridemia; ANGPTL3 for the treatment of hypertriglyceridemia and mixed hyperlipidemia; ALN-AGT for the treatment of hypertensive disorders of pregnancy, including preeclampsia; ALN-HBV for the treatment of Hepatitis B Virus; ALN-HDV for the treatment of HDV infection; and ALN-PDL for the treatment of chronic liver infections. The company has strategic alliances and collaboration agreements with Genzyme Corporation; The Medicines Company; Monsanto Company; F. Hoffmann-La Roche Ltd; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Tekmira Pharmaceuticals Corporation; The University of British Columbia; Acuitas Therapeutics Inc.; Takeda Pharmaceutical Company Limited; Protiva Biotherapeutics, Inc.; Biogen Idec Inc.; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Cubist Pharmaceuticals, Inc.; and Ascletis BioScience Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Alnylam Pharmaceuticals, Inc.

    Corporate Governance 
    Alnylam Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jul 1, 2015 is 9. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 10; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. John K. Clarke , 61
    Founder, Chairman, Chairman of Nominating & Corp. Governance Committee and Member of Audit Committee
    60.00KN/A
    Dr. John M. Maraganore M.D., Ph.D., 52
    Chief Exec. Officer and Exec. Director
    1.14M25.28M
    Mr. Barry E. Greene , 52
    Pres and Chief Operating Officer
    798.00K5.28M
    Mr. Michael P. Mason , 40
    VP of Fin. and Treasurer
    345.00K1.77M
    Ms. Laurie Bartlett Keating , 61
    Sr. VP, Gen. Counsel and Sec.
    269.00K0.00
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders